Buserelin

Gonadotropin-Releasing Hormone analog restoring CFTR channel function

Phase of research

EMA-approved for Other Purpose

How it helps

Restore CFTR Function

General information

Buserelin is a more potent synthetic analog of gonadotropin-releasing hormone. It was approved in 1985 for medical use. Buserelin is not available in the USA but is marketed in Europe and elsewhere. It is used in prostate cancer treatment. In relation to cystic fibrosis, our AIM tool found the data that buserelin can alleviate F508del-CFTR channel defects, most likely by elevating cAMP levels and increasing the amount of F508del-CFTR in cell membranes.

Buserelin on PubChem
Buserelin on DrugBank
Buserelin on Wikipedia

Synonyms

N/A

Marketed as

N/A

Dietary sources

N/A

Structure image not available

C₆₀H₈₆N₁₆O₁₃

Drug-Mutation Relation

results for D1152H / F508del

See all data on Buserelin

Treats

Mutation	Link	Tested on	Impact factor	Notes
F508del	Buserelin alleviates chloride transport defect in human cystic fibrosis nasal epithelial cells.	human cell cultures	2.77

Does not treat

Mutation	Link	Tested on	Impact factor	Notes